MACSF

COMMUNIQUÉS West-GlobeNewswire

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer
25/07/2025
MINNEAPOLIS, July 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the Company will hold a [...]
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
25/07/2025
Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo, but did not meet statistical significance on the primary [...]
IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025
25/07/2025
ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 second quarter financial results before the market opens on Friday, August 1, [...]
Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025
25/07/2025
DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands, with a [...]
Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025
25/07/2025
SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with [...]
PharmAla Issues Q3 Financial Statements
25/07/2025
TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
iSpecimen Inc. Announces Closing of $4 Million Underwritten Offering
25/07/2025
WOBURN, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc . (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a [...]
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
25/07/2025
The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the [...]
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
25/07/2025
The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the [...]
GUERBET : Descriptif du programme de rachat d’actions autorisé par l’Assemblée Générale Mixte du 23 mai 2025
25/07/2025
Descriptif du programme de rachat d’actions autorisé par l’Assemblée Générale Mixte du 23 mai 2025 Villepinte, le 25 juillet 2025 Conformément aux dispositions des articles 241-1 et suivants du Règlement général de l’ [...]
Wellcome Photography Prize 2025: Winning Images Reveal Powerful Stories of Science and Health
25/07/2025
Sujata Setia, Mithail Afrige Chowdhury and Steve Gschmeissner awarded £10,000 each for images exploring domestic abuse, climate migration and the hidden dangers of cholesterol A Thousand Cuts, Sujata Setia, 2023, Urban [...]
European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors
25/07/2025
Pending European Commission (EC) approval, Alhemo ® will become available to all adult and paediatric patients 12 years and older living with severe haemophilia A and moderate or severe haemophilia B without inhibitors [...]
Roche provides regulatory update on Elevidys™ gene therapy for Duchenne muscular dystrophy in the EU
25/07/2025
EMA’s CHMP issued an opinion not to recommend Elevidys™ (delandistrogene moxeparvovec) for the treatment of ambulatory individuals with Duchenne muscular dystrophy (DMD) Roche will continue its dialogue with the EMA to [...]
Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV Infection
25/07/2025
Results show biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients No safety or tolerability concerns were observed Supports progression into Phase III development with the potential to [...]
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)
25/07/2025
Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years. The primary endpoint was met in 27.8% of patients, confirming the efficacy in children and [...]
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
25/07/2025
The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional leadership, vision and values while guiding Houston's most successful and impactful organizations [...]
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
25/07/2025
CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion [...]
BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025
25/07/2025
PHILADELPHIA and VANCOUVER, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company [...]
La Commission européenne approuve DARZALEX® (daratumumab) comme premier traitement autorisé pour les patients présentant un myélome multiple indolent à haut risque
25/07/2025
Cette approbation historique repose sur les résultats de l’étude de la Phase 3 AQUILA, qui ont démontré qu’un traitement de durée fixe par daratumumab permettait de réduire significativement de 51 pour cent le risque de [...]

Pages